



Nail Burak ÖZBEYAZ<sup>1, a</sup>  
Engin ALGÜL<sup>2, b</sup>  
Hilal ERKEN PAMUKCU<sup>2, c</sup>

<sup>1</sup> TR Ministry of Health,  
Pursaklar State Hospital,  
Cardiology Clinic,  
Ankara, TURKIYE

<sup>2</sup> TR Ministry of Health,  
Etilik City Hospital,  
Cardiology Clinic,  
Ankara, TURKIYE

<sup>a</sup> ORCID: 0000-0002-7132-4286

<sup>b</sup> ORCID: 0000-0003-1539-4738

<sup>c</sup> ORCID: 0000-0001-8116-5090

## Whole Blood Viscosity Predicts Amputation in Patients With Lower Extremity Peripheral Arterial Disease

**Objective:** This study aims to find the relationship between whole blood viscosity (WBV) and amputation events occurring within 1 year of patients with lower extremity peripheral arterial (LEPAD) disease who cannot be revascularized by surgical or percutaneous methods.

**Materials and Methods:** The study retrospectively examined the data of 261 LEPAD patients with critical limb ischemia. WBV values of the patients were found with a formulation obtained from the total protein and hematocrit values in the blood samples (Simone's formula).

**Results:** Amputation developed in 51 (19.6%) patients. Hemoglobin, hematocrit, white blood cell count, neutrophil, platelet, WBV at high shear rate (HSR) (16.58±2.13 vs. 15.74±1.47, p<0.001) and WBV at low shear rate (LSR) of patients with amputation (100.15±14.97 vs. 92.84±13.39, p=0.002) value was found to be higher. As a result of multivariate regression analysis, WBV at HSR (OR: 1.096 95%CI (1.067-1.182), p=0.002) and WBV at LSR (OR: 6.481 95%CI (4.102-9.486), p<0.001) were found to be independent risk factors indicating the development of amputation. As a result of the receiver operating characteristics curve analysis, the cut-off value showing amputation for WBV at HSR is 16.34 (69% sensitivity, 68.6% specificity, and area under the curve (AUC): 0.728(0.532-0.823), p=0.005), a cut-off value indicating amputation for WBV at LSR is 97.48 (71.5%) sensitivity, specificity of 70.2% and AUC: 0.736(0.551-0.842), p=0.003).

**Conclusions:** According to the shear rate, both WBV values were found predictive of amputation in patients with critical limb ischemia who could not be revascularized.

**Key Words:** Whole blood viscosity, peripheral artery disease, critical limb ischemia, amputation

### Alt Ekstremitte Periferik Arter Hastalığı Olan Hastalarda Tam Kan Viskozitesi Amputasyonu Ön Gördürebilmektedir

**Amaç:** Bu çalışmada amaç; alt ekstremitte periferik arter hastalığı olan ve cerrahi ya da perkütan yöntemlerle revaskülarize edilemeyen hastaların 1 yıl içerisinde gelişen amputasyon olaylarının tam kan viskozitesi (TKV) ile ilişkisini bulmaktır.

**Gereç ve Yöntem:** Çalışma kritik ekstremitte iskemisi olan 261 tane AE-PAH hastasının verileri retrospektif olarak incelenerek yapılmıştır. Hastaların TKV değerleri alınan kan örneklerindeki total protein ve hematokrit değerlerinden elde edilen bir formülasyon ile bulunmuştur. Analiz için SPSS 23.0 programı kullanılmıştır.

**Bulgular:** 51 (19.6%) hastada amputasyon gelişmiştir. Amputasyon gelişen hastaların hemoglobin, hematokrit, beyaz kan hücresi sayısı, nötrofil, platelet, yüksek kesme oranında (YKO) TKV (16.58±2.13 vs. 15.74±1.47, p<0.001) ve düşük kesme oranında (DKO) TKV (100.15±14.97 vs. 92.84±13.39, p=0.002) değeri daha yüksek bulunmuştur. Çoklu regresyon analizi sonucunda YKOTKV (OR: 1.096 95%CI (1.067-1.182), p=0.002) ve DKOTKV (OR: 6.481 95%CI (4.102-9.486), p<0.001) amputasyon gelişimini gösteren bağımsız risk faktörleri olarak bulunmuştur. Yapılan alıcı işlem karakteristikleri eğrisi analizi sonucunda YKOTKV için amputasyonu gösteren kesme değeri 16.34 (%69 sensitivite, %68.6 spesifite ve eğri altında kalan alan (EAA): 0.728(0.532-0.823), p=0.005), DKOTKV için amputasyonu gösteren kesme değeri 97.48 (%71.5 sensitivite, %70.2 spesifite ve EAA: 0.736(0.551-0.842), p=0.003) olarak bulunmuştur.

**Sonuç:** Kesme oranlarına göre her iki TKV değeri de kritik ekstremitte iskemisi olan ve revaskülarize edilemeyen hastalarda amputasyon gelişimini öngördüren değerler olarak bulunmuşlardır.

**Anahtar Kelimeler:** Tam kan viskozitesi, periferik arter hastalığı, kritik ekstremitte iskemisi, amputasyon

### Introduction

Peripheral arterial disease (PAD) is a relatively common chronic disease characterized by decreased blood flow due to the narrowing of the vessel lumen and subsequently reduced oxygen delivery to tissues. And lower extremity (LE) PAD is the most common form in daily practice. LEPAD can vary from asymptomatic to critical limb-threatening ischemia (CLTI), which is the most challenging situation to manage medically in patients with PAD and can cause extremity loss. CLTI is by definition, ischemic pain at rest with or without tissue loss and has been shown in the literature to occur in 11% of PAD patients (1). Mortality in CLTI patients is higher than any other

Received : 03.12.2022  
Accepted : 25.08.2023

### Yazışma Adresi Correspondence

Nail Burak ÖZBEYAZ  
TR Ministry of Health,  
Pursaklar State Hospital,  
Cardiology Clinic,  
Ankara, TURKIYE

drozbeyaz@gmail.com

occlusive cardiovascular disease, including symptomatic coronary artery disease. While annual mortality in CLTI patients varies between 10% and 40%, 5-year mortality exceeds 50% (2-4). In addition to this increased mortality, 6-month extremity loss in CLTI patients can be seen at rates ranging from 10% to 40% (5-7). Although amputation rates have decreased in these patients with newly developed treatment techniques, it is crucial to identify CLTI patients who may undergo amputation, especially in patients who do not have a revascularization option, in terms of providing increased awareness and improvements in wound care (4, 8).

Although revascularization is the primary treatment option in treating CLTI, some patients are unsuitable for revascularization due to anatomical and physiological reasons (9). In addition to medical treatment, treatment options such as lumbar sympathectomy, spinal cord stimulation, hemodilution and intermittent pneumatic compression have been recommended for these patients (9-11). Indeed, Kim et al. showed that hemodilution therapy reduces major amputation in CLTI patients without a revascularization option (10). The physiological rationale of hemodilution therapy is that despite the decrease in hemoglobin level, the reduction in blood viscosity increases tissue perfusion (12). Although the hemoglobin level, which is essential for oxygen delivery to the tissue, decreases in this treatment option, the improvement in blood viscosity increases tissue oxygenation, suggesting that blood viscosity is an important clinical determinant in CLTI patients. Besides, the effectiveness of whole blood viscosity (WBV) as an important predictor in different cardiovascular diseases has been shown in the literature (13, 14). Based on this, we planned to investigate whether whole blood viscosity predicts amputation in CLTI patients unsuitable for revascularization.

## Materials and Methods

**Research and Publication Ethics:** Ethics committee approval was received from the ethics committee of the University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey (Date number: 14.05.2018, number: 50/16). The work was carried out in accordance with the principles of the Helsinki Declaration.

For this retrospective study, 684 patients who underwent invasive lower extremity peripheral angiography diagnosed with LEPAD CLTI between September 2016 and November 2021 were screened. A total of 261 patients who met the criteria of being technically unsuitable for revascularization or having previously experienced an unsuccessful revascularization procedure and having pain at rest (Rutherford grade 2-3) were included in the study. Patients with a body mass index (BMI) below 18 kg/m<sup>2</sup>, acute arterial disease, major tissue loss, liver failure, kidney disease, acute or chronic infection, chronic inflammatory disease, hematological disease, heart failure, oncological disease, use the anticoagulant treatment for any reason and patients whose follow-up

data cannot be accessed from hospital records were excluded from the study. In the formula used by De Simone et al. to calculate WBV, since it is recommended to use patients with plasma total protein values of 5.4–9.5 g/100 mL and values of 32-53% for HCT, patients with values outside these ranges were also excluded from the study (15, 16). The patients included in the study were divided into two groups as amputated and not amputated within one year.

The patients' blood results before the procedure were obtained from the hospital automation system, and the biochemistry and whole blood count values required for analysis were recorded. The complete blood test was evaluated using an automatic hematology analyzer (Symex XN-550 analyzer, Symex, Kobe, Japan) and biochemical tests using standard biochemical methods with Beckman Coulter LH 780 device (Beckman Coulter Inc., Brea, New York, USA). WBV values were calculated using Simone's formula, using hematocrit (HTC) and total protein (TP) concentration for both high shear rate (HSR=208 s<sup>-1</sup>) and low shear rate (LSR=0.5 s<sup>-1</sup>). For HSR,  $WBV (208 \text{ s}^{-1}) = (0.12 \times \text{HTC}) + 0.17 (\text{TP} - 2.07)$ , for LSR,  $WBV (0.5 \text{ s}^{-1}) = (1.89 \times \text{HTC}) + 3.76 (\text{TP} - 78.42)$  formulas were used. HTC is in %, TP is in g/l and WBV is whole blood viscosity in centipoise (cP) (15,16).

**Statistical Analysis:** Categorical data are presented as numbers and percentages. All the variables were examined with the Kolmogorov–Smirnov test for normality and the Levene test for homogeneity of variances before significance tests were used and normally distributed homogeneous data were used with the t-test in independent groups. The Mann–Whitney U test was used to evaluate the difference in the parameters that did not show normal distribution. For non-parametric data analysis, the chi-square test was used. Multivariate and univariate logistic regression was done to analyze the defined risk factors for amputation development and determine independent risk factors. Receiver operating characteristic (ROC) analysis was done to estimate the optimal cut-off value of WBV at HSR, WBV at LSR, and HCT in indicating amputation. Sensitivity, specificity, and area under the curve (AUC) values were calculated. The significance level was accepted  $p < 0.05$  2-sided for all statistical analyses. All data was analyzed using IBM SPSS Statistics (IBM Corp., Armonk, NY, USA) for Windows.

## Results

261 patients were included in the study. 193 (73.9%) of the patients were male. Amputation occurred in 51 (19.6%) of the patients included in the study. There was no difference between the demographic characteristics of the patients. As a result of laboratory analysis, hemoglobin, hematocrit, white blood cell (WBC), neutrophil, platelet, WBV at HSR, and WBV at LSR values of amputated patients were found to be higher than those of non-amputee patients (Table 1). On the contrary, total protein levels were found to be lower in amputated patients ( $6.73 \pm 1.02$  vs.  $6.99 \pm 0.80$ ,  $p = 0.027$ ).

**Table 1.** Basal demographic and laboratory characteristics of the patients according to amputation status

<b>Demographics</b>	<b>Amputees, n=51</b>	<b>Non-amputees, n=210</b>	<b>p</b>
Age (years), mean (SD)	66.1±10.2	64.5±9.4	0.371
Male gender n (%)	33(66.0)	160(76.2)	0.098
Smoking n (%)	29(56.9)	108(51.7)	0.306
Dyslipidemia n (%)	22(43.1)	113(53.8)	0.113
DM n (%)	28(54.9)	117(55.7)	0.274
HT n (%)	35(68.6)	116(55.2)	0.066
CAD n (%)	13(25.5)	61(29.2)	0.368
<b>Laboratory parameters</b>			
Hemoglobin (g/dL)	12.15±2.39	13.22±2.57	<b>0.004</b>
Hematocrit (%)	35.71±6.65	39.11±7.67	<b>0.002</b>
WBC (10 <sup>3</sup> /μL)	9.61±3.43	8.40±1.91	<b>0.019</b>
Neutrophil (10 <sup>3</sup> /μL)	6.57±3.18	5.61±1.72	<b>0.043</b>
Platelets (mm <sup>3</sup> )	306.62±42.53	271.2±34.16	<b>0.030</b>
Total protein (g/dL)	6.73±1.02	6.99±0.80	<b>0.027</b>
Albumin (g/dL)	3.57 ± 0.32	3.68±0.72	0.513
LDL-C (mg/dL)	126.21±38.13	122.38±41.07	0.565
HDL-C (mg/dL)	38.86±11.26	38.95±13.57	0.963
Triglycerides (mg/dL)	166.46±52.44	159.78±49.69	0.651
Creatinine (mg/dL)	1.34±0.76	1.29±0.86	0.086
BUN (mg/dL)	51.01±23.98	46.86±22.78	0.514
Glucose (mg/dL)	143.61±65.68	134.27±54.34	0.137
WBV at HSR	16.58±2.13	15.74±1.47	<b>&lt;0.001</b>
WBV at LSR	100.15±14.97	92.84±13.39	<b>0.002</b>

DM: Diabetes mellitus, HT: Hypertension, CAD: Coronary artery disease, WBC: White blood cell, RDW: red cell distribution width LDL: Low-density lipoprotein, HDL: high-density Lipoprotein, WBV: Whole blood viscosity, HSR: High shear rate, LSR: Low shear rate.

**Table 2.** Regression analysis results in predictive factors for amputation

	<b>Univariable Analysis</b>		<b>Multivariable Analysis</b>	
	<b>OR (95% CI)</b>	<b>p</b>	<b>OR (95% CI)</b>	<b>p</b>
Hemoglobin	0.979(0.966-0.993)	<b>0.004</b>	0.985(0.970-1.002)	0.069
Hematocrit	0.932(0.890-0.977)	<b>0.003</b>	0.891(0.765-1.237)	0.349
WBC	1.149(1.025-1.258)	<b>0.020</b>	0.804(0.543-1.191)	0.276
Neutrophil	1.138(1.002-1.257)	<b>0.047</b>	1.038(0.682-1.580)	0.862
Platelet	1.003(1.001-1.006)	<b>0.033</b>	1.003(1.001-1.006)	0.038
Total protein	0.614(0.404-0.932)	<b>0.024</b>	0.833(0.522-1.329)	0.443
WBV at HSR	1.083(1.059–1.137)	<b>0.001</b>	1.096(1.067-1.182)	<b>0.002</b>
WBV at LSR	6.362(3.605–9.208)	<b>&lt;0.001</b>	6.481(4.102-9.486)	<b>&lt;0.001</b>

WBC: White Blood Cell, WBV: Whole blood viscosity, HSR: High shear rate, LSR: Low shear rate.

Multivariate and univariate logistic regression analyses were performed to investigate the predictive factors for amputation. Hemoglobin, hematocrit, WBC, neutrophil, platelet, total protein, WBV at HSR, and WBV at LSR were found to be good predictor factors for amputation ( $p=0.004$ ,  $p=0.003$ ,  $p=0.020$ ,  $p=0.047$ ,  $p=0.033$ ,  $p=0.024$ ,  $p=0.001$ ,  $p<0.001$ , respectively). When all the factors that were affected the amputation by multivariate regression analysis were examined, WBV at HSR (OR (95%CI) 1.096(1.067-1.182),  $p=0.002$ ) and WBV at LSR (OR (95%CI) 6.481(4.102-9.486),  $p<0.001$ )


were determined as independent risk factors for amputation (Table 2).

ROC curve analysis for WBV at HSR and WBV at LSR showed that the ideal cut-off values of WBV at HSR and WBV at LSR as a predictor of amputation was 16.34 (69.0 % sensitivity and 68.8% specificity) for WBV at HSR and 97.48 (71.5% sensitivity and 70.2% specificity) for WBV at LSR. The AUC for WBV at HSR was found to be 0.728 (95% CI 0.532-0.823;  $p=0.005$ ), and the AUC for WBV at LSR was found to be 0.736 (95% CI 0.551-0.842;  $p=0.003$ ) (Figure 1) (Table 3).

**Table 3.** Receiver operating characteristic curve analysis results for amputation

Risk Factor	AUC (95%)	Cut- Off	p	Sensitivity (%)	Specificity (%)
Hematocrit	0.629(0.504-0.713)	37.65	<b>0.004</b>	58.6	66.9
Total Protein	0.577(0.476-0.677)	***	0.089	***	***
WBV at HSR	0.728(0.532-0.823)	16.34	<b>0.005</b>	69.0	68.8
WBV at LSR	0.736(0.551-0.842)	97.48	<b>0.003</b>	71.5	70.2

WBV: Whole blood viscosity, HSR: High shear rate, LSR: Low shear rate, AUC: area under the curve



**Figure 1.** Receiver operating characteristic curve analysis table for amputation

**Discussion**

Our study showed that WBV at both shear rates was significantly higher in those undergoing amputation in patients with LEPAD who did not have the option of revascularization. Our study also showed that WBV is a strong independent risk factor for amputation in the same patient group.

Although the primary treatment recommended for CLTI patients is revascularization, different treatment protocols have been proposed for patients who cannot be revascularized due to various reasons. One of them is the hemodilution method. It is thought that the main effect of the hemodilution therapy is the positive effect on the plasma viscosity and the increased flow in the micro-vessels (12, 17, 18). As a matter of fact, it has been shown in the literature that WBV is improved with hemodilution therapy. Kim et al. (10) showed that despite the decrease in hemoglobin levels with hemodilution therapy in patients with CLTI, the tissue oxygen delivery index increased due to improved WBV,

which was reflected in positive clinical results. Considering all of the above, it is seen that WBV is the treatment target that has an essential place in physiopathogenesis in patients with LEPAD. Especially in patients with multiple, long collateralized vascular obstructions, such as CLTI patients, WBV is an important factor determining endothelial shear stress, thus increasing its clinical importance in this patient group (19).

In addition to the above, the atherosclerosis process is significantly influenced by hemorheological factors has been shown in the literature that increased blood viscosity plays a vital role in the atherosclerotic process by causing intravascular stasis and endothelial dysfunction (20). A high degree of blood viscosity causes turbulent blood flow that exacerbates endothelial disruption and impairs endothelial integrity and function (21-23). Apart from the atherosclerotic process, endothelial shear stress also affects atherosclerotic plaque rupture and thrombosis formation (24, 25). As the

main determinant of endothelial shear stress, WBV has an important role in this physiopathological pathway. As a matter of fact, Erdogan et al. showed that WBV was significantly higher in patients presenting with acute arterial occlusion compared to the control group (26).

Viscometers such as falling-ball, capillary, and rotational viscometers are used for viscosity measurements (27). However, access to these methods is limited in daily clinical practice. The formula we used in our study, defined by Simone, provides important data on WBV through total protein level and complete blood count, which we commonly use in routine practice. With the formula described by Simone, estimated WBV values can be obtained at different shear rates (15). Compared to the viscometer-measured analysis, the estimated WBV values calculated with the formula described by Simone demonstrated a smaller degree of error (15).

## References

1. Aboyans V, Ricco J-B, Bartelink M-L, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). *Kardiologia Polska (Polish Heart Journal)* 2017; 75: 1065-1160.
2. Bradbury AW, Ruckley C, Fowkes F, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): Multicentre, randomised controlled trial. *Lancet* 2005; 366: 1925-1934.
3. Stoyioglou A, Jaff MR. Medical treatment of peripheral arterial disease: A comprehensive review. *Journal of Vascular and Interventional Radiology* 2004; 15: 1197-1207.
4. Teraa M, Conte MS, Moll FL, Verhaar MC. Critical limb ischemia: Current trends and future directions. *Journal of the American Heart Association* 2016; 5: e002938.
5. Steffen MW, Undavalli C, Asi N, et al. The natural history of untreated severe or critical limb ischemia. *Journal of Vascular Surgery* 2015; 62: 1642-1651.
6. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *European Journal of Vascular & Endovascular Surgery* 2007; 33: 1-75.
7. Becker F, Robert-Ebadi H, Ricco JB, et al. definitions, epidemiology, clinical presentation and prognosis. *European Journal of Vascular and Endovascular Surgery* 2011; 42: S4-S12.
8. Chung J, Modrall JG, Ahn C, Lavery LA, Valentine RJ. Multidisciplinary care improves amputation-free survival in patients with chronic critical limb ischemia. *Journal of Vascular Surgery* 2015; 61: 162-169.
9. Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. *European Journal of Vascular and Endovascular Surgery* 2019; 58: S1-S109.
10. Kim D, Cho DJ, Cho YI. Reduced amputation rate with isovolemic hemodilution in critical limb ischemia patients. *Clinical Hemorheology and Microcirculation* 2017; 67: 197-208.
11. Ernst E, Kollar L, Matrai A. Hemodilution in peripheral arterial occlusive disease. Placebo controlled randomized double-blind study with hydroxyethyl starch or dextran. *Acta Medica Austriaca* 1991; 18: 27-29.
12. Salazar Vázquez B, Martini J, Chávez Negrete A, et al. Cardiovascular benefits in moderate increases of blood and plasma viscosity surpass those associated with lowering viscosity: Experimental and clinical evidence. *Clinical Hemorheology and Microcirculation* 2010; 44: 75-85.
13. Cetin EHO, Cetin MS, Canpolat U, et al. Prognostic significance of whole blood viscosity estimated by de Simone's formula in ST-elevation myocardial infarction. *Biomarkers in Medicine* 2016; 10: 495-511.
14. Cowan AQ, Cho DJ, Rosenson RS. Importance of blood rheology in the pathophysiology of atherothrombosis. *Cardiovascular Drugs and Therapy* 2012; 26: 339-348.
15. de Simone G, Devereux RB, Chien S, et al. Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults. *Circulation* 1990; 81: 107-117.
16. de Simone G, Devereux RB, Chinali M, et al. Association of blood pressure with blood viscosity in American Indians: the Strong Heart Study. *Hypertension* 2005; 45: 625-630.
17. Wilhelm H, Jung F, Kiesewetter H, Recktenwald C. On haemodilution therapy for patients with sudden loss of hearing: clinical and rheological results. *Klin Wochenschr* 1986; 64: 1058-1061.
18. Özbeyaz NB, Aydinylmaz F, Guliyev İ, et al. Diz altı periferik arter hastalığında albümin-kreatinin oranının bir yıllık amputasyon riski ile ilişkisi. *MN Cardiology/MN Kardioloji* 2022; 29: 144-150.
19. Cho YI, Cho DJ, Rosenson RS. Endothelial shear stress and blood viscosity in peripheral arterial disease. *Current Atherosclerosis Reports* 2014; 16: 1-10.
20. Chatzizisis YS, Coskun AU, Jonas M, et al. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: Molecular,

- cellular, and vascular behavior. *Journal of the American College of Cardiology* 2007; 49: 2379-2393.
21. Kensey K, Cho Y, Chang M. Effects of whole blood viscosity on atherogenesis. *The Journal of Invasive Cardiology* 1997; 9: 17-24.
  22. Ciuffetti G, Schillaci G, Lombardini R, et al. Prognostic impact of low-shear whole blood viscosity in hypertensive men. *European Journal of Clinical Investigation* 2005; 35: 93-98.
  23. Ozbeyaz NB, Gokalp G, Algul E, et al. Platelet-hemoglobin ratio predicts amputation in patients with below-knee peripheral arterial disease. *BMC Cardiovasc Disord* 2022; 22: 337.
  24. Kim J, Chung H, Cho M, et al. The role of critical shear stress on acute coronary syndrome. *Clinical Hemorheology and Microcirculation* 2013; 55: 101-109.
  25. Cecchi E, Giglioli C, Valente S, et al. Role of hemodynamic shear stress in cardiovascular disease. *Atherosclerosis* 2011; 214: 249-256.
  26. Erdoğan G, Yenerçağ M, Arslan U. The relationship between blood viscosity and acute arterial occlusion. *J Cardiovasc Emergencies* 2020; 6: 7-12.
  27. Schramm G. *A practical approach to rheology and rheometry*: Haake Karlsruhe; 1994.